ArticleRenal failure2021
Value of contrast-enhanced ultrasonography in radiofrequency ablation of secondary hyperparathyroidism.
Article in Renal failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Complications in chemical and thermal ablation of parathyroid lesions: a systematic review and meta-analysis.European radiology · 2025Pooled it
- Efficacy and safety of radiofrequency ablation for hyperparathyroidism: a meta-analysis and systematic review.European radiology · 2025Pooled it
- Radiofrequency ablation as an alternative treatment for hyperparathyroidism: a case study of a single parathyroid adenoma and review of the literature.Hormones (Athens, Greece) · 2026Review
- Efficacy and safety of radiofrequency ablation for secondary hyperparathyroidism: a systematic review and meta-analysis.Asian biomedicine : research, reviews and news · 2024Article
- Ultrasound-Guided Radiofrequency Ablation in Tertiary Hyperparathyroidism: A Prospective Study.Korean journal of radiology · 2024Article
- Complications after radiofrequency ablation of hyperparathyroidism secondary to chronic kidney disease.Renal failure · 2023Article
- Efficacy and safety of radiofrequency ablation for primary and secondary hyperparathyroidism: a retrospective study.Scientific reports · 2023Article
- Localization Strategy Prior to Radiofrequency Ablation for Primary and Secondary Hyperparathyroidism.Biomedicines · 2023Article
- Massive hemorrhage arising of inferior thyroid artery by radiofrequency ablation for secondary hyperparathyroidism: Two case reports.Medicine · 2022Article
- The value of clinical-ultrasonographic feature model to predict the severity of secondary hyperparathyroidism.Renal failure · 2022Observational
- Evaluation of efficacy of ultrasound-guided microwave ablation in primary hyperparathyroidism.Journal of clinical ultrasound : JCU · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe purpose of the current study was to determine the performance of contrast-enhanced ultrasound (CEUS) in the assessment of radiofrequency ablation (RFA) of hyperplastic parathyroid glands due to secondary hyperparathyroidism (SHPT).
methodsThirty-two patients, each with ≥4 hyperplastic parathyroid glands due to SHPT, underwent RFA
resultsAblation was achieved in all patients (131 ablated glands). The volume of the glands was 479.88 ± 549.3mm
conclusionsCEUS-guided RFA is effective and feasible for the treatment of ≥4 hyperplastic parathyroid glands. CEUS was shown to assist the surgeon before, during, and after RFA. CEUS on post-operative day 2, but not immediately post-operatively, was shown to accurately reflect gland perfusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.